Elutia Gestione
Criteri Gestione verificati 3/4
Elutia Il CEO è Randy Mills, nominato in Jun2022, e ha un mandato di 3.92 anni. la retribuzione annua totale è $ 1.34M, composta da 44.6% di stipendio e 55.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.93% delle azioni della società, per un valore di $ 474.91K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.8 anni e 5.7 anni.
Informazioni chiave
Randy Mills
Amministratore delegato
US$1.3m
Compenso totale
| Percentuale dello stipendio del CEO | 44.63% |
| Mandato del CEO | 3.9yrs |
| Proprietà del CEO | 0.9% |
| Durata media del management | 3.8yrs |
| Durata media del Consiglio di amministrazione | 5.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Mar 04
ELUT: Listing Compliance Recovery Will Support Future Reconstructive Portfolio Upside
Analysts have adjusted their price target on Elutia to reflect updated views on profitability, with a lower assumed profit margin and a higher future P/E estimate shaping the new valuation in dollar terms. What's in the News Elutia received a written notice from Nasdaq on December 23, 2025 stating that it is not in compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2) (Key Developments).Aggiornamento della narrazione • Feb 18
ELUT: Listing Compliance Progress Will Support Future Reconstructive Portfolio Upside
Analysts have revised their price target on Elutia to $3.50, maintaining their fair value estimate while updating assumptions on the discount rate, revenue growth, profit margin, and future P/E to align with their current assessment of the company’s risk and earnings profile. What's in the News Elutia received a written notice from Nasdaq stating that it is not in compliance with the minimum market value of listed securities requirement of $35m under Listing Rule 5550(b)(2).Articolo di analisi • Feb 15
Elutia Inc. (NASDAQ:ELUT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone. But...
Aggiornamento della narrazione • Feb 04
ELUT: Future Nasdaq Compliance Resolution Will Support Bullish Repricing Potential
Analysts have maintained their price target on Elutia at US$5.00, citing a slightly lower discount rate, a modest change in expected revenue contraction, and a small adjustment to future P/E assumptions, along with a slightly higher projected profit margin. What's in the News On December 23, 2025, Elutia received a Nasdaq notice that its market value of listed securities had been below the US$35 million minimum for 30 consecutive business days, and that it also did not meet certain shareholder equity and net income standards required for continued listing on The Nasdaq Capital Market (Nasdaq notice).Aggiornamento della narrazione • Jan 21
ELUT: Future Nasdaq Compliance Progress Will Drive Bullish Repricing Potential
Narrative Update on Elutia Analysts have maintained their price target for Elutia at US$5.00, citing slightly lower assumed revenue growth, a modestly higher profit margin outlook, and a small adjustment to the discount rate and future P/E assumptions as key drivers behind the updated view. What's in the News On December 23, 2025, Nasdaq notified Elutia that its market value of listed securities had been below the US$35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive business days, and that the company also did not meet related shareholder equity or net income standards (Nasdaq notice).Aggiornamento della narrazione • Jan 07
ELUT: Future Compliance Recovery Will Support Bullish Repricing Potential
Analysts have reduced their price target on Elutia by US$1.00. They cite a higher discount rate, a projected revenue decline of 7.18%, and a much higher future P/E estimate, partly offset by slightly stronger expected profit margins.Aggiornamento della narrazione • Dec 16
ELUT: Future Listing Compliance Efforts Will Support Reconstructive Portfolio Expansion
Narrative Update on Elutia Analysts have modestly adjusted their price target on Elutia upward to reflect a slightly more constructive long term earnings and valuation outlook, nudging the fair value estimate higher by approximately $0.00 per share as updated model inputs had only a de minimis impact on the overall target. What's in the News Elutia received a notice from Nasdaq that its Class A common stock has traded below the $1.00 per share minimum bid price for 30 consecutive business days, triggering a formal deficiency notification and potential delisting process (Nasdaq listing notice).Articolo di analisi • Dec 06
Lacklustre Performance Is Driving Elutia Inc.'s (NASDAQ:ELUT) 28% Price Drop
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 28% in the last...Aggiornamento della narrazione • Dec 02
ELUT: Recent Business Sale Will Fund Breast Reconstruction Growth Ahead
Analysts have lowered Elutia's target price from $8.00 to $6.00, citing a smaller-than-expected sale price for the BioEnvelope business. However, they note that the deal removes significant overhangs and provides full funding for Elutia's breast reconstruction segment.Aggiornamento della narrazione • Nov 17
ELUT: Recent Business Sale Will Unlock Breast Reconstruction Focus
Narrative Update on Elutia Elutia's analyst price target has been reduced from $8 to $6 following analysts’ assessment that, although the sale of the BioEnvelope business provides significant funding, the lower-than-expected acquisition price tempers near-term expectations for the company's growth. Analyst Commentary Analysts have weighed in on the implications of Elutia's recent business developments, offering a nuanced perspective on the company's outlook.Aggiornamento della narrazione • Nov 01
ELUT: Breast Reconstruction Funding Will Drive Long-Term Shareholder Value
Elutia's analyst price target has decreased from $8 to $6, as analysts factor in the sale of its BioEnvelope business. While this sale is seen as bittersweet, it helps eliminate notable uncertainties and secures funding for the company's breast reconstruction segment.Aggiornamento della narrazione • Oct 17
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia from $8 to $6 per share, citing both the lower-than-expected sale price of its BioEnvelope business and the improved funding outlook for its core breast reconstruction segment. Analyst Commentary Recent analyst reports provide a nuanced view of Elutia's prospects following the BioEnvelope business sale.Articolo di analisi • Oct 13
The Market Doesn't Like What It Sees From Elutia Inc.'s (NASDAQ:ELUT) Revenues Yet As Shares Tumble 30%
To the annoyance of some shareholders, Elutia Inc. ( NASDAQ:ELUT ) shares are down a considerable 30% in the last...Aggiornamento della narrazione • Oct 03
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Analysts have reduced their price target for Elutia, with recent adjustments citing a new range from $8 to $5 per share. This reflects cautious optimism about the firm's strategic divestiture and future growth prospects, despite near-term revenue challenges.Aggiornamento della narrazione • Sep 10
Aging Demographics And Chronic Conditions Will Spur Healing Advances
Elutia's fair value estimate has been revised downward due to sharply reduced revenue growth forecasts and a significantly higher future P/E multiple, resulting in the consensus price target dropping from $6.50 to $5.50. What's in the News Elutia was selected to exhibit its EluPro Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange, providing exposure to hospital supply chain and clinical leaders.Articolo di analisi • Aug 29
Elutia Inc.'s (NASDAQ:ELUT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Elutia Inc. ( NASDAQ:ELUT ) shareholders have had their patience rewarded with a 27% share price jump in the last...Articolo di analisi • Aug 19
US$6.50: That's What Analysts Think Elutia Inc. (NASDAQ:ELUT) Is Worth After Its Latest Results
NasdaqCM:ELUT 1 Year Share Price vs Fair Value Explore Elutia's Fair Values from the Community and select yours Elutia...Aggiornamento della narrazione • Aug 19
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
Despite a substantial increase in consensus revenue growth forecasts and a sharply lower future P/E, Elutia’s consensus analyst price target has been reduced from $7.50 to $6.50. What's in the News Elutia published a study showing its antibiotic-eluting CIED biologic envelope, EluPro, controls inflammation, supports vascularization, and promotes higher growth factor release, potentially reducing scarring and infection risks in implantable cardiac device patients.Articolo di analisi • Jun 18
Revenues Working Against Elutia Inc.'s (NASDAQ:ELUT) Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Elutia Inc. ( NASDAQ:ELUT ) may be sending very bullish signals at the...
Nuova narrazione • Apr 06
FDA Cleared EluPro Launch And Capacity Expansion Will Unlock Opportunity
EluPro's FDA clearance and market entry against Medtronic's TYRX could drive significant revenue growth in the antibiotic-eluting envelope space.Articolo di analisi • Jan 04
Elutia Inc. (NASDAQ:ELUT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Elutia Inc. ( NASDAQ:ELUT ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Articolo di analisi • Nov 20
Elutia Inc. (NASDAQ:ELUT) Held Back By Insufficient Growth Even After Shares Climb 26%
Elutia Inc. ( NASDAQ:ELUT ) shareholders would be excited to see that the share price has had a great month, posting a...Articolo di analisi • Jun 28
Elutia Inc.'s (NASDAQ:ELUT) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Elutia Inc. ( NASDAQ:ELUT ) shares have continued their recent momentum with a 28% gain in the last month alone...Articolo di analisi • Mar 10
News Flash: 2 Analysts Think Elutia Inc. (NASDAQ:ELUT) Earnings Are Under Threat
One thing we could say about the analysts on Elutia Inc. ( NASDAQ:ELUT ) - they aren't optimistic, having just made a...Articolo di analisi • Feb 21
Elutia Inc.'s (NASDAQ:ELUT) Share Price Is Matching Sentiment Around Its Revenues
You may think that with a price-to-sales (or "P/S") ratio of 1.5x Elutia Inc. ( NASDAQ:ELUT ) is definitely a stock...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$22m |
| Dec 31 2025 | US$1m | US$600k | -US$16m |
| Sep 30 2025 | n/a | n/a | -US$25m |
| Jun 30 2025 | n/a | n/a | -US$22m |
| Mar 31 2025 | n/a | n/a | -US$40m |
| Dec 31 2024 | US$5m | US$600k | -US$45m |
| Sep 30 2024 | n/a | n/a | -US$53m |
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$2m | US$600k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$35m |
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | US$2m | US$321k | -US$36m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$146k | n/a | -US$25m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$142k | n/a | -US$25m |
Compensazione vs Mercato: La retribuzione totale di Randy ($USD 1.34M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 626.93K ).
Compensazione vs guadagni: La retribuzione di Randy è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Randy Mills (53 yo)
3.9yrs
Mandato
US$1,344,284
Compensazione
Dr. C. Randal Mills, Ph D., also known as Randy, has been Director of Elutia Inc. (formerly known as Aziyo Biologics, Inc.) since November 2015. Dr. Mills served as a Member of Advisory Board at eXpanded e...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 3.9yrs | US$1.34m | 0.93% $ 474.9k | |
| Chief Financial Officer | 5.7yrs | US$747.03k | 1.07% $ 547.6k | |
| Chief Scientific Officer | 3.8yrs | US$688.70k | 0.25% $ 127.4k | |
| Head of People | less than a year | Nessun dato | Nessun dato | |
| VP & Head of Emerging Businesses | 4.3yrs | Nessun dato | Nessun dato | |
| Head of Cardiovascular | 1yr | Nessun dato | Nessun dato | |
| Chief Commercial Officer | less than a year | Nessun dato | Nessun dato | |
| Senior VP of Finance | no data | Nessun dato | Nessun dato |
3.8yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di ELUT è considerato esperto (durata media dell'incarico 3.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 10.5yrs | US$1.34m | 0.93% $ 474.9k | |
| Independent Chairman & Lead Independent Director | 10.5yrs | US$321.50k | 1.17% $ 601.5k | |
| Independent Director | 5.7yrs | US$161.00k | 0.061% $ 31.3k | |
| Independent Director | less than a year | US$196.25k | 0.28% $ 145.0k | |
| Independent Director | 3.6yrs | US$138.50k | 0.070% $ 36.1k |
5.7yrs
Durata media
64yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ELUT sono considerati esperti (durata media dell'incarico 5.7 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/25 06:50 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Elutia Inc. è coperta da 6 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |